FIELD: pharmacology.
SUBSTANCE: invention relates to new peptides having the activity of NPR-B agonists that can be used to treat and prevent disorders mediated by natriuretic peptides, for example, such as glaucoma, eye hypertension and optical neuropathies.
EFFECT: increased efficiency of treatment.
21 cl, 3 dwg, 5 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL NRP-B AGONISTS | 2010 |
|
RU2557290C2 |
| VERSIONS OF C-TYPE NATRIURETIC PEPTIDE | 2010 |
|
RU2573911C2 |
| USE OF OPTIONS OF NATRIURETIC PEPTIDE OF TYPE C FOR TREATMENT OF OSTEOARTHRITIS | 2016 |
|
RU2759679C2 |
| CONTROLLED RELEASE COMBINATION THERAPY WITH CNP AGONISTS | 2017 |
|
RU2768747C2 |
| APPLICATION OF VARIANTS OF NATRIURETIC PEPTIDE OF C-TYPE FOR TREATMENT OF SKELETAL DYSPLASIA | 2016 |
|
RU2728567C2 |
| DIPEPTIDE LINKED MEDICINAL AGENTS | 2009 |
|
RU2578591C2 |
| ATRIAL NATRIURETIC PEPTIDE GRAFTED ANTIBODIES | 2019 |
|
RU2822433C2 |
| GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE RECEPTOR ACTIVITY | 2011 |
|
RU2604067C2 |
| SYNTHETIC PEPTIDE AMIDES AND THEIR DIMERS | 2007 |
|
RU2510399C2 |
| APPLICATION OF C-TYPE NATRIURETIC PEPTIDE VARIANTS FOR THE TREATMENT OF SKELETAL DYSPLASIA | 2016 |
|
RU2794515C2 |
